Gelsolin (GSN) Gene Mutation Analysis
Gelsolin (GSN) is an actin-binding protein belonging to a diverse family of proteins including adseverin, CapG, villin, supervillin, and advillin. Gelsolin modulates the actin filament assembly by severing, capping, and nucleating actin filaments. This modulation is pivotal in maintaining normal cellular morphology and function. Gelsolin is abundantly expressed in lungs and cardiac tissues and moderately expressed in skeletal muscles, testes, and kidneys.
Mutations in the GSN gene result in an autosomal dominant condition termed lattice corneal dystrophy type II (LCD-II), also known as familial amyloidosis Finnish type (FAF). LCD-II is characterized by systemic deposition of gelsolin amyloid fibrils predominantly in the cornea, skin, and nerves. Clinical manifestations typically start in adulthood and progress over time.
Primary clinical features include corneal lattice dystrophy, presenting as lattice-patterned corneal opacities causing visual impairment, recurrent erosions, and photophobia, progressive cranial neuropathy, particularly facial nerve paralysis, peripheral neuropathy with sensory and motor deficits predominantly affecting extremities and cutaneous manifestations such as sagging skin (cutis laxa).
Early genetic diagnosis via GSN mutation analysis facilitates prompt clinical intervention, genetic counseling, and surveillance of affected individuals and family members.
- Confirmation of the genetic diagnosis of lattice corneal dystrophy type II
- Differential diagnosis in patients presenting with unexplained peripheral neuropathy, visual disturbances, and characteristic skin manifestations
- Identification of asymptomatic carriers for early clinical monitoring and preventive care
Positive Result: Indicates presence of pathogenic GSN mutations consistent with lattice corneal dystrophy type II. Confirms or supports clinical diagnosis and informs familial genetic risk.
Negative Result: Indicates absence of known pathogenic mutations in GSN gene; significantly reduces, but does not completely exclude, the risk of lattice corneal dystrophy type II. Additional genetic or clinical evaluations may be warranted depending on patient symptoms and family history.
Negative (no pathogenic mutation identified)
Whole blood (EDTA tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 21 days
- Expert Rev Mol Med. 2019 Jan 30;20:e7. [PMID: 30698126]
- Am J Hum Genet. 1992 Jul;51(1):156-60. [PMID: 1319113]
- Handb Clin Neurol. 2013;115:659-81. [PMID: 23931809]
- N Engl J Med. 1991 Dec 19;325(25):1780-5. [PMID: 1658654]
- Handb Clin Neurol. 2013;115:659-81. [PMID: 23931809 ]
- Cell Mol Life Sci. 2004 Oct;61(19-20):2614-23. [PMID: 15526166]
- Biomedicines. 2022 Mar 21;10(3):723. [PMID: 35327525]